Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm Invests 170 Million Yen in Regenerative Medicine Startup
May 11, 2017
- Takeda, UK Bioventure GammaDelta Pair Up for Development of New Immunotherapies Based on T cells
May 11, 2017
- Sales Rep Survey - 2: Drug Makers Exploring New Values amid Shift to Community-Based Care
May 10, 2017
- Meiji Seika Pharma Forms Generic Subsidiary
May 10, 2017
- Takeda Calls off Hib Vaccine Launch on GSK’s Production Exit
May 10, 2017
- Japanese Drug Production Could Shrink to 6.8 Trillion Yen in 2024: Yano Research Institute
May 10, 2017
- BIKEN, Mitsubishi Tanabe Reach Final Agreement on Vaccine Joint Venture Slated to Begin Operation in September
May 10, 2017
- Daiichi Sankyo Starts Edoxaban Clinical Study in AF Patients following TAVI
May 10, 2017
- Eisai Suffers Setback in US Patent Litigation over Aloxi
May 9, 2017
- Mitsubishi Tanabe’s ALS Med Gets FDA Greenlight
May 9, 2017
- Sales Rep Survey - 1: Foreign Drug Makers’ Downsizing Drive Unabated
May 9, 2017
- 60% of Drug Makers Increase New Grad Hires in FY2017, Otsuka Tops List: Jiho Tally
May 9, 2017
- Brexpiprazole Delivers Mixed Results on AD Agitation: Otsuka, Lundbeck
May 8, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Dismissed: Nichi-Iko
May 8, 2017
- Takeda Gets FDA Nod for Ariad’s ALK Hopeful Brigatinib
May 8, 2017
- Keytruda Filed in Japan for Urothelial Cancer: MSD
April 28, 2017
- Harvoni Filed for Genotype 2 Hepatitis C: Gilead Japan
April 28, 2017
- Takeda Joins Hands with Harrington Institute on Rare Disease Therapeutics
April 28, 2017
- Pfizer Files Japan NDA for ALL Treatment
April 28, 2017
- Certican Filed in Japan for Liver Transplant Rejection: Novartis
April 28, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…